Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5883

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor  

Yang, Li-Min (Department of Orthopaedics, The First Affiliated Hospital of Liaoning Medical College)
Li, Xiu-Hua (Department of Orthopaedics, The First Affiliated Hospital of Liaoning Medical College)
Bao, Cui-Fen (Central Laboratory of Liaoning Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5883-5886 More about this Journal
Abstract
Osteosarcoma is the most common primary bone malignancy in children and adolescents, and its clinical outcome is poor. We evaluated the response of GSTP1, ERCC1 and ERCC2 to chemotherapy among osteosarcoma patients, and the role of these genes on the prognosis of osteosarcoma. 187 patients with osteosarcoma were administered with methotrexate, cisplatin/adriamycin, actinomycin D, cyclophosphamide, or vincristine treatment. GSTP1, ERCC1 and ERCC2 polymorphism was genotyped by PCR-RFLP assay. The results showed the average survival time of 187 patients were 38.4 months. 97 patients showed response to neoadjuvant chemotherapy. The GSTP1 Val and ERCC2 A/A genotypes had significantly higher rates of response to chemotherapy, with adjusted OR (95% CI) of 2.19 (1.15-6.21) and 2.88 (1.14-13.25). Individuals with ERCC2 A/A genotype were likely to have a lower risk of death from oseosarcoma, and the adjusted HR was 0.32 (0.13-0.95). Our study indicated test of GSTP1 and ERCC2 Lys751Gln polymorphisms might be a candidate pharmacogenomic factors to be explored in the future to identify the osteosarcoma patients who might benefit from chemotherapy.
Keywords
GSTP1; DNA repaird gene; chemotherapy; polymorphisms; response;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Caronia D, Patino-Garcia A, Milne RL, et al (2009). Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-53.   DOI   ScienceOn
2 Fuchs B, Zhang K, Schabel A, et al (2001). Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene, 278, 245-52.   DOI
3 Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev, 11, 1513-30.
4 Hao T, Feng W, Zhang J, Sun YJ, Wang G (2012). Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients. Asian Pac J Cancer Prev, 13, 3821-4.   DOI   ScienceOn
5 Hengstler JG, Arand M, Herrero ME, et al (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase, and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res, 154, 47-85.   DOI
6 Ketterer B (1988). The protective role of glutathione transferases in mutagenesis and carcinogenesis. Mutat Res, 202, 343-61.   DOI
7 Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8.   DOI
8 Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-234.   DOI
9 Pasello M, Manara MC, Michelacci F, et al (2011). Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst), 34, 131-45.   DOI
10 Pasello M, Michelacci F, Scionti I, et al (2008). Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res, 68, 6661-8.   DOI
11 Riddick DS, Lee C, Ramji S, et al (2005). Cancer chemotherapy and drug metabolism. Drug Metab Dispos, 33, 1083-96.   DOI
12 Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42.   DOI
13 U.S. Cancer Statistics Working Group (2009). United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Available at: http://www.cdc. gov/cancer/npcr/npcrpdfs/US_Cancer_Statistics_2004_Incidence_and_Mortality.pdf. Oct. 2011.
14 Windsor RE, Strauss SJ, Kallis C, et al (2012). Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, 118, 1856-67.   DOI   ScienceOn
15 Zimniak P, Nanduri B, Pikula S, et al (1994). Naturally occurring human glutathione S-transferase GSTP-1 isoforms with isoleucin and valine in position 104 differ in enzymic properties. Eur J Biochem, 224, 893-9.   DOI   ScienceOn
16 Wang X, Zuckerman B, Pearson C, et al (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 287, 195-202.   DOI
17 Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B, Sun YJ (2012). Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev, 13, 2705-9.   DOI